SuperworthZevra Therapeutics shares outstanding ZVRA
Diluted shares outstanding, averaged over each quarter, from 2014.
- Latest quarter, to Jun 30, 2026
- 61.3M
- On a year earlier
- +8.9%
- more shares
Zevra Therapeutics had 61.3M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 8.9% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 58.7M | +10% |
| FY2024 | 53.4M | +51% |
| FY2021 | 35.3M | +678% |
| FY2020 | 4.5M | +118% |
| FY2019 | 2.1M | +31% |
| FY2018 | 1.6M | +74% |
| FY2017 | 916.1K | +0% |
| FY2016 | 915.4K | +515% |
| FY2014 | 148.8K | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 61.3M | +9% | |
| Q1 FY26 | 60.2M | +11% | |
| Q4 FY25 | 58.7M | +10% | |
| Q3 FY25 | 56M | +17% | |
| Q2 FY25 | 56.3M | +34% | |
| Q1 FY25 | 54.1M | n/a | |
| Q4 FY24 | 53.4M | n/a | |
| Q3 FY24 | 47.8M | n/a | |
| Q2 FY24 | 41.9M | n/a | |
| Q4 FY21 | 35.3M | +678% | |
| Q3 FY21 | 35.2M | +696% | |
| Q2 FY21 | 29.2M | +639% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Zevra Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.